December 26, 2023 Experience HighTide Therapeutics HK$194.1 million IPO We advised HighTide Therapeutics on its IPO and HKEX listing
June 14, 2023 Experience Cutia Therapeutics HK$412.9 million IPO We advised Cutia on its IPO and HKEX listing
April 28, 2023 Experience MedSci Healthcare Holdings HK$608 million IPO We advised MedSci on its IPO and HKEX listing
April 14, 2023 Experience Beisen Holding HK$155 million IPO We advised Beisen on its IPO and HKEX listing
September 22, 2022 Experience InnoCare Pharma RMB2.9 billion Shanghai IPO This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far
September 19, 2022 Experience Interra Acquisition HK$1 billion IPO We advised the SPAC on its IPO and HKEX listing
September 1, 2022 Experience Biocytogen HK$549 million IPO We advised Biocytogen on its IPO and HKEX listing